Financial Comparison: 10x Genomics (NASDAQ:TXG) vs. MSP Recovery (NASDAQ:MSPR)

10x Genomics (NASDAQ:TXG) and MSP Recovery (NASDAQ:MSPR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Risk and Volatility

10x Genomics has a beta of 2.24, meaning that its share price is 124% more volatile than the S&P 500. Comparatively, MSP Recovery has a beta of -2.93, meaning that its share price is 393% less volatile than the S&P 500.

Profitability

This table compares 10x Genomics and MSP Recovery’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-11.89%	-11.50%	-8.93%
MSP Recovery	-7,328.48%	-326.80%	-81.27%

Insider and Institutional Ownership

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 3.8% of MSP Recovery shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 50.5% of MSP Recovery shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for 10x Genomics and MSP Recovery, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	3	9	4	0	2.06
MSP Recovery	1	0	0	0	1.00

10x Genomics presently has a consensus target price of $16.83, indicating a potential downside of 4.90%. Given 10x Genomics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe 10x Genomics is more favorable than MSP Recovery.

Valuation & Earnings

This table compares 10x Genomics and MSP Recovery”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$610.78 million	3.67	-$182.63 million	($0.62)	-28.55
MSP Recovery	$9.81 million	0.05	-$360.50 million	($572.83)	0.00

10x Genomics has higher revenue and earnings than MSP Recovery. 10x Genomics is trading at a lower price-to-earnings ratio than MSP Recovery, indicating that it is currently the more affordable of the two stocks.

Summary

10x Genomics beats MSP Recovery on 12 of the 14 factors compared between the two stocks.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

About MSP Recovery

MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.